- Home
- MITK vs CAPR Comparison
MITK vs CAPR Comparison
Compare MITK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITK
- CAPR
- Stock Information
- Founded
- MITK 1983
- CAPR 2005
- Country
- MITK United States
- CAPR United States
- Employees
- MITK N/A
- CAPR N/A
- Industry
- MITK Computer peripheral equipment
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MITK Technology
- CAPR Health Care
- Exchange
- MITK Nasdaq
- CAPR Nasdaq
- Market Cap
- MITK 411.7M
- CAPR 392.8M
- IPO Year
- MITK N/A
- CAPR N/A
- Fundamental
- Price
- MITK $7.65
- CAPR $11.25
- Analyst Decision
- MITK Strong Buy
- CAPR Strong Buy
- Analyst Count
- MITK 4
- CAPR 7
- Target Price
- MITK $12.88
- CAPR $39.29
- AVG Volume (30 Days)
- MITK 474.2K
- CAPR 1.4M
- Earning Date
- MITK 05-09-2025
- CAPR 05-12-2025
- Dividend Yield
- MITK N/A
- CAPR N/A
- EPS Growth
- MITK N/A
- CAPR N/A
- EPS
- MITK 0.10
- CAPR N/A
- Revenue
- MITK $172,420,000.00
- CAPR $22,270,465.00
- Revenue This Year
- MITK $4.03
- CAPR $78.85
- Revenue Next Year
- MITK $8.97
- CAPR $157.99
- P/E Ratio
- MITK $79.41
- CAPR N/A
- Revenue Growth
- MITK 5.28
- CAPR N/A
- 52 Week Low
- MITK $6.93
- CAPR $3.52
- 52 Week High
- MITK $14.32
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- MITK 38.24
- CAPR 52.49
- Support Level
- MITK $7.46
- CAPR $9.43
- Resistance Level
- MITK $7.94
- CAPR $10.09
- Average True Range (ATR)
- MITK 0.38
- CAPR 0.93
- MACD
- MITK 0.03
- CAPR 0.22
- Stochastic Oscillator
- MITK 47.06
- CAPR 97.82
About MITK Mitek Systems Inc.
Mitek Systems Inc is engaged in the development, sale, and service of proprietary software solutions related to mobile imaging. The firm is a software development company with expertise in artificial intelligence, and machine learning. It serves more than 7,900 financial services organizations, financial technology (fintech) brands, telecommunications companies, and marketplace brands across the globe. The company's Mobile Deposit solution is used by consumers for mobile check deposits. The company's Mobile Verify verifies a user's identity online enabling organizations to build safer digital communities, whereas CheckReader enables financial institutions to automatically extract data from a check image received across any deposit channel - branch, ATM, RDC, and mobile.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.